NK Cell Therapies
Artiva's NK Cell Therapy Pipeline
| Program | Target | Indication | Preclinical | Phase 1 | Phase 2 | Partner |
ADCC Enhancer, Non-Genetically Modified NK |
||||||
| AlloNK® | + CD20 mAb | B-Cell Malignancies | ||||
| AlloNK® | + AFM13 | CD30+ Lymphomas |
|
|||
| AlloNK® | + Rituximab | Lupus Nephritis | ||||
Targeted CAR-NK |
||||||
| AB-201 | HER2 | HER2+ Cancers | ||||
| AB-205 | CD5 | T-Cell Lymphoma |
|
|||
| AB-MK | Not Disclosed | Solid Tumor |
|
|||
Non-Genetically Modified ADCC-Enhancer NK Cells
AlloNK®
AlloNK® (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva selects cord blood units with the high affinity variant of the receptor CD16 and a KIR-B haplotype for enhanced product activity. Using the company’s cell therapy manufacturing platform, Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other activating NK receptors, without the need for engineering.
AlloNK® + Anti-CD20 Monoclonal Antibodies in Non-Hodgkin Lymphoma
Our ongoing Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT04673617) is assessing the safety and clinical activity of AlloNK® alone and in combination with the anti-CD20 monoclonal antibody, rituximab. The study is enrolling patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) who have progressed beyond two or more prior lines of therapy.
AlloNK® + AFM-13 in CD30-Positive Lymphomas
Artiva and Affimed have entered into a strategic collaboration to jointly develop, manufacture, and commercialize a combination therapy comprised of Artiva’s, AlloNK®, and Affimed’s Innate Cell Engager (ICE®) AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.
AlloNK® + Rituximab in Lupus Nephritis
Artiva is investigating the safety and clinical activity of AlloNK in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis.
Genetically Modified CAR-NK Cells
AB-201: HER2 CAR-NK
AB-201 is our clinical-stage CAR-NK cell therapy candidate targeting HER2-positive solid tumors. We and our partner, GC Cell, are initiating the clinical evaluation of AB-201. The studies will assess AB-201 safety and efficacy in HER2+ breast and gastric/GEJ carcinomas. AB-201 HER2 CAR-NK uses a novel, high affinity HER2-directed antibody converted to Artiva’s proprietary CAR structure and expression of IL-15 for improved cellular persistence. AB-201 cell products maintain high expression of CD16, as well as other activating innate cell tumor engaging receptors, enabling the potential for dual targeting therapeutic approaches via monoclonal antibody combinations. The resulting CAR-NK is manufactured at large scale and cryopreserved in infusion-ready media to enable repeat clinical administrations in the outpatient setting.
AB-205 CD5-Directed CAR-NK
AB-205 has been developed preclinically by Artiva’s strategic partner, GC Cell, for the treatment of CD5+ lymphomas of T-cell origin. AB-205 is currently in IND-enablement studies.
Partnered Programs
Artiva and Merck have entered into an exclusive worldwide research and development collaboration and license agreement to develop novel CAR-NK cell therapies for solid tumors. The collaboration leverages Artiva’s off-the-shelf allogeneic NK cell manufacturing AlloNKTM platform and proprietary CAR-NK technology. The collaboration includes two CAR-NK programs. Under the agreement, Artiva is responsible for initial development through the first GMP manufacturing campaign and IND preparation, followed by transfer of the applicable program to Merck for clinical and commercial development.
Artiva and Affimed have entered into a strategic collaboration to jointly develop, manufacture, and commercialize a combination therapy comprised of AlloNK® and Affimed’s Innate Cell Engager (ICE®) AFM13. The clinical agreement follows the parties’ previous two-year preclinical collaboration to assess combining elements of the companies’ respective platforms in the generation of targeted, off-the-shelf allogeneic NK cell therapies. As part of the collaboration, the companies evaluated the combination of AFM13 and AB101 in various preclinical models and generated data that supports development of a co-administered combination therapy.
Expanded Access Policy
immediately life-threatening condition or serious disease to gain access to an investigational drug for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.We are focused on enrolling and conducting the clinical trials necessary to bring innovative, safe, and effective products to patients as quickly as possible. Participation in one of our clinical trials is the only way to access Artiva’s investigational products at this time. We encourage patients and healthcare providers interested in our investigational products to learn more about our ongoing studies by visiting Artiva Clinical Studies. For more information, please contact us at info@artivabio.com.